Vyleesi (Bremelanotide) and Life Events That Affect Dosing

How Bremelanotide Works on Demand

Bremelanotide is a melanocortin-4 receptor (MC4R) agonist that acts on central nervous system pathways involved in sexual desire [1]. Unlike daily oral medications, it is injected subcutaneously in the abdomen or thigh only when a woman anticipates sexual activity. The FDA approved it in June 2019 based on two phase 3 trials (RECONNECT 1 and RECONNECT 2), which enrolled a combined 1,247 premenopausal women with HSDD [2].

Pharmacokinetic Profile

Peak plasma concentration occurs roughly 1 hour after injection, with a half-life of approximately 2.7 hours [1]. This short duration means effects are largely confined to the day of dosing. Because the drug clears quickly, life events that alter metabolism, blood flow, or hormonal status can shift both efficacy and side-effect intensity from dose to dose.

Why Life Events Matter for an On-Demand Drug

A daily medication reaches steady state, smoothing over day-to-day physiological variation. Bremelanotide does not. Each injection is its own pharmacokinetic event. A woman who injects after a transatlantic flight, during acute illness, or while managing perioperative recovery may experience a meaningfully different response than she would under routine circumstances [3].

Pregnancy and Fertility Planning

Bremelanotide is contraindicated during pregnancy. Animal studies using doses 10 times the human exposure showed reduced fetal growth and developmental delays [1]. No adequate human data exist.

Before Conception

Women actively trying to conceive should stop bremelanotide before discontinuing contraception. The drug's short half-life means it clears within 24 hours, but the FDA labeling advises discussing the timeline with a prescriber [1]. There is no evidence that prior use impairs fertility.

Unplanned Pregnancy

If pregnancy is confirmed after a recent dose, the exposure window is narrow given the 2.7-hour half-life. A single inadvertent dose is unlikely to produce sustained fetal exposure, but the prescribing information directs immediate discontinuation and referral to obstetric care [1].

Fertility Treatments

Women undergoing IVF or ovulation induction should not use bremelanotide during treatment cycles. Gonadotropin protocols alter hormonal milieu in ways that have not been studied alongside MC4R agonism, and the transient blood pressure rise could complicate ovarian hyperstimulation monitoring [4].

Breastfeeding and Postpartum Use

No human lactation data exist for bremelanotide. The molecular weight (1,025 Da) suggests limited transfer into breast milk, but this has not been confirmed [1]. The FDA label states that breastfeeding is not recommended during use.

Postpartum HSDD Context

HSDD symptoms frequently emerge or worsen postpartum, driven by falling estradiol, elevated prolactin, sleep deprivation, and psychosocial stressors [5]. This creates a clinical tension: the population most likely to seek treatment is the one for whom safety data are absent. Clinicians managing postpartum HSDD typically consider behavioral therapy or off-label alternatives with more established lactation safety profiles before reintroducing bremelanotide after weaning [6].

Cardiovascular Considerations and Blood Pressure

Bremelanotide produces a transient increase in systolic blood pressure of approximately 6 mmHg and diastolic blood pressure of approximately 3 mmHg, peaking 2 to 4 hours post-injection and resolving within 12 hours [1]. Heart rate decreases by a mean of 5 to 6 beats per minute during this window.

Uncontrolled Hypertension

The label explicitly warns against use in women with uncontrolled hypertension or known cardiovascular disease [1]. "Uncontrolled" is generally defined as resting blood pressure consistently at or above 140/90 mmHg on repeated measurement per AHA/ACC 2017 guidelines [7]. Women who develop hypertension while using bremelanotide should hold further doses until blood pressure is managed.

Acute Cardiovascular Events

Any acute event (myocardial infarction, stroke, hypertensive crisis) mandates permanent discontinuation. The transient pressor effect, while modest in healthy women, is an unacceptable risk superimposed on acute vascular compromise [1].

Concurrent Antihypertensive Medications

In the RECONNECT trials, women taking stable antihypertensives were included. The blood pressure increase was additive with naltrexone (which was an exclusion criterion for separate reasons) but did not show clinically significant interaction with ACE inhibitors, ARBs, or calcium channel blockers at the doses studied [2].

Hepatic and Renal Impairment

Liver Disease

Bremelanotide is metabolized through hydrolysis rather than CYP-mediated pathways [1]. In a dedicated hepatic impairment study, AUC increased by 30% in moderate impairment (Child-Pugh B) compared to matched controls, but peak concentration was unchanged. The FDA concluded no dose adjustment is required for mild-to-moderate hepatic impairment. Severe hepatic impairment (Child-Pugh C) has not been studied, and use is not recommended in that population [1].

Kidney Disease

In a renal impairment study, AUC increased by approximately 25% in women with eGFR 15 to 29 mL/min compared to women with normal kidney function [1]. Despite this, the FDA did not require dose adjustment for any studied stage. Women on dialysis were excluded from all trials. If a patient starts dialysis while previously using bremelanotide, re-evaluation with nephrology is warranted before any subsequent dose.

Surgery, Procedures, and Acute Illness

Elective Surgery

Bremelanotide should be held before elective surgery. The transient blood pressure rise and heart rate reduction could complicate anesthetic management. A reasonable washout is 24 hours given the 2.7-hour half-life and 12-hour hemodynamic effect window [1]. Anesthesiologists should be informed of recent use.

Perioperative Decision Framework

A practical approach: hold bremelanotide for 24 hours before any procedure requiring sedation or general anesthesia, resume only after the patient is fully ambulatory, eating normally, and off postoperative opioids. Opioids independently suppress sexual desire and add nausea burden on top of bremelanotide's 40% nausea rate [8].

Acute Illness

During febrile illness, gastroenteritis, or any condition causing dehydration, the blood pressure effects may be amplified or unpredictable. The nausea associated with bremelanotide (reported in 40% of subjects in the RECONNECT trials [2]) is poorly tolerated when layered onto illness-related nausea. Patients should skip doses during acute illness and resume when well.

Travel and Storage Logistics

Temperature-Sensitive Storage

Bremelanotide autoinjectors must be stored at 2 to 8°C (refrigerated). They may be kept at room temperature (up to 25°C) for a single period of up to 30 days, after which unused autoinjectors must be discarded [1]. This matters for travel: a week-long trip is manageable at room temperature, but a month abroad in a warm climate requires refrigeration planning.

Crossing Time Zones

Because bremelanotide is used on demand (not daily), jet lag does not create the dosing-interval confusion seen with daily medications. The relevant constraint remains the 24-hour minimum between doses. A woman who injects at 10 PM London time and flies to New York, arriving at a local 10 PM that is only 5 hours later by her body clock, must wait a full 24 hours from the original dose before injecting again [1].

Altitude

No studies have examined bremelanotide at high altitude. Hypoxia-induced increases in pulmonary artery pressure are theoretically additive with the drug's systemic pressor effect. Women traveling above 2,500 meters who have any cardiovascular risk factors should consult their prescriber before packing the autoinjector.

Alcohol, Recreational Substances, and Diet

Alcohol

The FDA label does not list a specific alcohol contraindication, but alcohol potentiates nausea and hypotension in the post-absorptive phase [1]. In the RECONNECT trials, moderate alcohol use was not an exclusion criterion, and no formal alcohol interaction study was conducted [2]. A conservative approach: limit intake to one standard drink within the 4-hour window around dosing.

Recreational Substances

Bremelanotide has no studied interactions with cannabis, MDMA, or stimulants. The melanocortin system intersects with dopaminergic reward pathways [9], raising theoretical concerns about unpredictable mood or cardiovascular responses when combined with psychoactive substances. No clinical guidance exists beyond the general principle of avoiding unstudied combinations with a drug that raises blood pressure.

Food Timing

Bremelanotide is injected, bypassing first-pass metabolism. Food does not affect bioavailability [1]. A heavy meal may delay gastric motility and compound the nausea side effect subjectively, but pharmacokinetics are unchanged.

Stress, Mental Health, and HSDD Overlap

Chronic Stress and Cortisol

HSDD is a biopsychosocial condition. Chronic stress elevates cortisol, which suppresses gonadotropin-releasing hormone and blunts the hypothalamic pathways that bremelanotide targets [10]. Women experiencing sustained occupational, relational, or financial stress may find the drug less effective during those periods. This does not mean the drug has failed. It means the underlying neuroendocrine environment has shifted.

Depression and Antidepressants

SSRI-induced sexual dysfunction and HSDD are distinct diagnoses, though they overlap clinically. Bremelanotide was not studied in women whose low desire was attributed solely to an SSRI [2]. Women on SSRIs who also meet DSM-5 criteria for HSDD may use bremelanotide, but they should be counseled that response rates in this subgroup are not well characterized. Flibanserin, the oral alternative, also lacks strong data in SSRI-treated populations [11].

Major Life Transitions

Divorce, bereavement, job loss, and relocation all suppress desire through psychological mechanisms that MC4R agonism does not directly address. Bremelanotide may still produce a physiological response, but patient satisfaction depends on addressing both biological and contextual factors. Cognitive behavioral therapy for sexual dysfunction has shown efficacy alongside pharmacotherapy in small trials [12].

Drug Interactions That Change With Life Stage

Hormonal Contraceptives

Bremelanotide reduced the exposure of oral ethinyl estradiol and levonorgestrel by approximately 20% when administered within 2 hours of the oral contraceptive dose [1]. The FDA recommends taking oral contraceptives at least 1 hour before or after bremelanotide injection. Women who switch to a long-acting reversible contraceptive (IUD, implant) eliminate this interaction entirely.

Naltrexone

Co-administration with naltrexone is explicitly not recommended. A pharmacodynamic interaction study showed significantly reduced efficacy of bremelanotide when given with naltrexone 50 mg, likely through opioid-melanocortin pathway crosstalk [1]. Women prescribed naltrexone for alcohol use disorder or opioid use disorder cannot use bremelanotide concurrently.

Perimenopause and Approaching Off-Label Territory

Bremelanotide is FDA-approved for premenopausal women only. As women approach perimenopause (typically ages 40 to 51, per the North American Menopause Society [13]), declining estradiol may reduce MC4R expression in hypothalamic nuclei, potentially diminishing drug response. The RECONNECT trials enrolled women 18 to 55 but reported limited subgroup data for participants older than 45 [2]. Women crossing into perimenopause while using bremelanotide should discuss continued use with their prescriber, as the evidence base narrows.

Monitoring and Follow-Up Recommendations

Prescribers should reassess bremelanotide at each of these life-event inflection points: new pregnancy attempt, postpartum period, new cardiovascular diagnosis, initiation of naltrexone, change in hepatic or renal function, and entry into perimenopause. The RECONNECT trials required follow-up every 4 weeks during the 24-week treatment phase [2]. In clinical practice, a reasonable schedule is an initial 4-week check-in after starting, then every 3 to 6 months unless a life event triggers earlier review. Blood pressure should be documented at baseline and at least once during follow-up, given the known pressor effect [1].

Women who experience persistent nausea (reported by 40% in trials, with 13% severity-related discontinuation [2]) should not assume this will resolve without intervention. Ondansetron 4 mg taken 30 minutes before the bremelanotide injection has been used off-label in clinical practice to manage this side effect, though no formal study supports the combination.